SEARCH

SEARCH BY CITATION

References

  • 1
    Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J & Wren BW (2012) Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol 61, 919926.
  • 2
    Huang CJ, Lin H & Yang X (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39, 383399.
  • 3
    Mattanovich D, Branduardi P, Dato L, Gasser B, Sauer M & Porro D (2012) Recombinant protein production in yeasts. Methods Mol Biol 824, 329358.
  • 4
    Pavsic M, Vito T & Lenarcic B (2008) Purification and characterization of a recombinant human testican-2 expressed in baculovirus-infected Sf9 insect cells. Protein Expr Purif 58, 132139.
  • 5
    McQuillan DJ, Seo NS, Hocking AM & McQuillan CI (2001) Recombinant expression of proteoglycans in mammalian cells. Utility and advantages of the vaccinia virus/T7 bacteriophage hybrid expression system. Methods Mol Biol 171, 201219.
  • 6
    Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30, 11581170.
  • 7
    Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M & Lortat-Jacob H (2010) Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology 20, 13801388.
  • 8
    Whitelock J, Ma J, Davies N, Nielsen N, Chuang C, Rees M, Iozzo RV, Knox S & Lord M (2008) Recombinant heparan sulfate for use in tissue engineering applications. J Chem Technol Biotechnol 83, 496504.
  • 9
    Knox S, Fosang AJ, Last K, Melrose J & Whitelock J (2005) Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan. FEBS Lett 579, 50195023.
  • 10
    Multhaupt HA & Couchman JR (2012) Heparan sulfate biosynthesis: methods for investigation of the heparanosome. J Histochem Cytochem 60, 908915.
  • 11
    Whitelock JM & Iozzo RV (2005) Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105, 27452764.
  • 12
    Baik JY, Gasimli L, Yang B, Datta P, Zhang F, Glass CA, Esko JD, Linhardt RJ & Sharfstein ST (2012) Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab Eng 14, 8190.
  • 13
    Nishiyama A, Lin XH & Stallcup WB (1995) Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Mol Biol Cell 6, 18191832.
  • 14
    Linhardt RJ & Liu J (2012) Synthetic heparin. Curr Opin Pharmacol 12, 217219.
  • 15
    Hocking AM, Shunomura T & McQuillan DJ (1998) Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17, 119.
  • 16
    Pearson CH, Winterbottom N, Fackre DS, Scott PG & Carpenter MR (1983) The NH2-terminal amino acid sequence of bovine skin proteodermatan sulfate. J Biol Chem 258, 1510115104.
  • 17
    Yamaguchi Y & Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336, 244246.
  • 18
    Tenni R, Viola M, Welser F, Sini P, Giudici C, Rossi A & Tira ME (2002) Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem 269, 14281437.
  • 19
    Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R & Hook M (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267, 52505256.
  • 20
    Ramamurthy P, Hocking AM & McQuillan DJ (1996) Recombinant decorin glycoforms. J Biol Chem 271, 1957819584.
  • 21
    von Marschall Z & Fisher LW (2010) Decorin is processed by three isoforms of bone morphogenetic protein-1 (BMP1). Biochem Biophys Res Commun 391, 13741378.
  • 22
    Al Haj Zen A, Lafont A, Durand E, Brasselet C, Lemarchand P, Godeau G & Gogly B (2003) Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts. Matrix Biol 22, 251258.
  • 23
    Shimizukawa M, Ebina M, Narumi K, Kikuchi T, Munakata H & Nukiwa T (2003) Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am J Physiol Lung Cell Mol Physiol 284, L526L532.
  • 24
    Kitagawa H, Oyama M, Masayama K, Yamaguchi Y & Sugahara K (1997) Structural variations in the glycosaminoglycan–protein linkage region of recombinant decorin expressed in Chinese hamster ovary cells. Glycobiology 7, 11751180.
  • 25
    Engel S, Isenmann S, Ständer M, Rieger J, Bähr M & Weller M (1999) Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. J Neuroimmunol 99, 1318.
  • 26
    Svensson L, Närlid I & Oldberg A (2000) Fibromodulin and lumican bind to the same region on collagen type I fibrils. FEBS Lett 470, 178182.
  • 27
    Reed CC, Gauldie J & Iozzo RV (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 36883695.
  • 28
    Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG & Lowenstein PR (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11, 721732.
  • 29
    Huijun W, Long C, Zhigang Z, Feng J & Muyi G (2005) Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 78, 1724.
  • 30
    Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT & Edwards IJ (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 10421053.
  • 31
    Sugars EV, Waddington RJ & Embery G (2002) The interaction of recombinant decorin with α2HS-glyocprotein – implications for structural and functional investigations. Protein Expr Purif 25, 180188.
  • 32
    Landrygan-Bakri J, Wilson MJ, Williams DW, Lewis MA & Waddington RJ (2012) Real-time monitoring of the adherence of Streptococcus anginosus group bacteria to extracellular matrix decorin and biglycan proteoglycans in biofilm formation. Res Microbiol 163, 436447.
  • 33
    Hering TM, Kollar J, Huynh TD & Varelas JB (1996) Purification and characterization of decorin core protein expressed in Escherichia coli as a maltose-binding protein fusion. Anal Biochem 240, 98108.
  • 34
    Gu J, Nakayama Y, Nagai K & Wada Y (1997) The production and purification of functional decorin in a baculovirus system. Biochem Biophys Res Commun 232, 9195.
  • 35
    Seo NS, Hocking AM, Höök M & McQuillan DJ (2005) Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions. J Biol Chem 280, 4277442784.
  • 36
    Geng Y, McQuillan DJ & Roughley PJ (2006) SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 25, 484491.
  • 37
    Kalamajski S, Aspberg A & Oldberg A (2007) The decorin sequence SYIRIADTNIT binds collagen type I. J Biol Chem 282, 1606216067.
  • 38
    Dugan TA, Yang VW, McQuillan DJ & Höök M (2003) Decorin binds fibrinogen in a Zn2+-dependent interaction. J Biol Chem 278, 1365513662.
  • 39
    Groeneveld TWL, Oroszlán M, Owens RT, Faber-Krob MC, Bakker AC, Arlaud GJ, McQuillan DJ, Kishore U, Daha MR & Roos A (2005) Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol 175, 47154723.
  • 40
    Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B & Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149157.
  • 41
    Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ & Iozzo RV (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173, 844855.
  • 42
    Grant DS, Yenisey C, Rose RW, Tootell M, Santra M & Iozzo RV (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 47654777.
  • 43
    Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Iino T et al. (2008) Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 19, 15331539.
  • 44
    Border WA, Noble NA, Yamamoto T, Tomooka S & Kagami S (1992) Antagonists of transforming growth factor-β: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. Kidney Int 41, 566570.
  • 45
    Masuda H, Takakura Y & Hashida M (1999) Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice. Biochim Biophys Acta 1426, 420428.
  • 46
    Logan A, Baird A & Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159, 504510.
  • 47
    Fukushima K, Badlani N, Usas A, Riano F, Fu F & Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29, 394402.
  • 48
    Järveläinen H, Vernon RB, Gooden MD, Francki A, Lara S, Johnson PY, Kinsella MG, Sage EH & Wight TN (2004) Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type I collagen in vitro. Arterioscler Thromb Vasc Biol 24, 6772.
  • 49
    Yan W, Wang P, Zhao CX, Tang J, Xiao X & Wang DW (2009) Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 20, 11901200.
  • 50
    Hocking AM, Strugnell RA, Ramamurthy P & McQuillan DJ (1996) Eukaryotic expression of recombinant biglycan. J Biol Chem 271, 1957119577.
  • 51
    Schönherr E, Beavan LA, Hausser H, Kresse H & Culp LA (1993) Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro. Biochem J 290, 893899.
  • 52
    Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609652.
  • 53
    Kresse H, Seidler DG, Muller M, Breuer E, Hausser H, Roughley PJ & Schonherr E (2001) Different usage of the glycosaminoglycan attachment sites of biglycan. J Biol Chem 276, 1341113416.
  • 54
    Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC & Fallon JR (2006) Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20, 17241726.
  • 55
    Svensson L, Heinegärd D & Oldberg A (1995) Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4–5. J Biol Chem 270, 2071220716.
  • 56
    Wiberg C, Heinegärd DW, Timpl R & Morgelin M (2002) Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures. J Biol Chem 277, 4912049126.
  • 57
    Schönherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J & Kresse H (1995) Interaction of biglycan with type I collagen. J Biol Chem 270, 27762783.
  • 58
    Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS & Fallon JR (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108, 762767.
  • 59
    Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Ownes RT, Hook M, McQuillan DJ, Young MF et al. (2006) Biglycan binds to α- and γ-sarcogylcan and regulates their expression during development. J Cell Physiol 209, 439447.
  • 60
    Miwa HE, Gerken TA, Huynh TD, Flory DM & Hering TM (2006) Mammalian expression of full-length bovine aggrecan and link protein: formation of recombinant proteoglycan aggregates and analysis of proteolytic cleavage by ADAMTS-4 and MMP-13. Biochim Biophys Acta 1760, 472486.
  • 61
    Kiani C, Lee V, Cao L, Chen L, Wu Y, Zhang Y, Adams ME & Yang BB (2001) Role of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 354, 199207.
  • 62
    Poon CJ, Plaas AH, Keene DR, McQuillan DJ, Last K & Fosang AJ (2005) N-linked keratan sulfate in the aggrecan interglobular domain potentiates aggrecanase activity. J Biomed 280, 2361523621.
  • 63
    Yang BB, Yang BL & Goetinick PF (1996) Construction and expression of a functional recombinant gene for proteoglycan. Ann NY Acad Sci 785, 356359.
  • 64
    Doege K, Chen X, Cornuet PK & Hassell J (1997) Non-glycosaminoglycan bearing domains of perlecan and aggrecan influence the utilization of sites for heparan and chondroitin sulfate synthesis. Matrix Biol 16, 211221.
  • 65
    Cao L, Zhang Y & Yang BB (1998) Expression of the G1 domain of aggrecan interferes with chondrocyte attachment and adhesion. Matrix Biol 17, 379392.
  • 66
    Li LN, Zhang DQ, Zhou KY, Cartman A, Leroux JY, Poole AR & Zhang YP (2000) Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res 10, 3949.
  • 67
    Shi S, Ciurli C, Cartman A, Pidoux I, Poole AR & Zhang Y (2003) Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 48, 29032915.
  • 68
    Oliver BL, Cronin CG, Bue C, Hand AR & Tanzer ML (2003) Two alanines juxtaposed to aggrecan's G1 domain alter its intracellular localisation. J Cell Biochem 90, 592607.
  • 69
    Watanabe H, Cheung SC, Itano N, Kimata K & Yamada Y (1997) Identification of hyaluronan-binding domains of aggrecan. J Biol Chem 272, 2805728065.
  • 70
    Chen TLL, Wang PY, Luo W, Gwon SS, Flay NW, Zheng J, Guo C, Tanzer ML & Vertel BM (2001) Aggrecan domains expected to traffic through the exocytic pathway are misdirected to the nucleus. Exp Cell Res 263, 224235.
  • 71
    Fushimi K, Troeberg L, Nakamura H, Lim NH & Nagase H (2008) Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 283, 67066716.
  • 72
    Hughes CE, Buttner FH, Eidenmuller B, Caterson B & Bartnik E (1997) Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecananse in cell culture systems. J Biol Chem 272, 2026920274.
  • 73
    Mercuri FA, Doege KJ, Arner EC, Pratta MA, Last K & Fosang AJ (1999) Recombinant human aggrecan G1–G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase. J Biol Chem 274, 3238732395.
  • 74
    Halberg DF, Proulx G, Doege K, Yamada Y & Drickamer K (1988) A segment of the cartilage proteoglycan core protein has lectin-like activity. J Biol Chem 263, 94869490.
  • 75
    Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE & Bayliss MT (1996) Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J 313, 933940.
  • 76
    Kiani C, Chen L, Lee V, Zheng PS, Wu Y, Wen J, Cao L, Adams ME, Sheng W & Yang BB (2003) Identification of the motifs and amino acids in aggrecan G1 and G2 domains involved in product secretion. Biochemistry 42, 72267237.
  • 77
    Luo W, Kuwada TS, Chandrasekaran L, Zheng J & Tanzer ML (1996) Divergent secretory behaviour of the opposite ends of aggrecan. J Biol Chem 271, 1644716450.
  • 78
    Chen L, Wu Y, Lee V, Kiani C, Adams ME, Yao Y & Yang BB (2002) The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion. J Biol Chem 277, 26572665.
  • 79
    Lee V, Chen L, Paiwand F, Cao L, Wu Y, Inman R, Adams ME & Yang BB (2002) Cleavage of the carboxyl tail from the G3 domain of aggrecan but not versican and identification of the amino acids involved in the degradation. J Biol Chem 277, 2227922288.
  • 80
    Miwa HE, Gerken TA & Hering TM (2006) Effects of covalently attached chondroitin sulfate on aggrecan cleavage by ADAMTS-4 and MMP-13. Matrix Biol 25, 534545.
  • 81
    Day JM, Olin AI, Murdoch AD, Canfield A, Sasaki T, Timpl R, Hardingham TE & Aspberg A (2004) Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem 279, 1251112518.
  • 82
    Retzler C, Gohring W & Rauch U (1996) Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM. J Biol Chem 271, 2730427310.
  • 83
    Milev P, Fischer D, Haring M, Schulthess T, Margolis RK, Chiquet-Ehrismann R & Margolis RU (1997) The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta. J Biol Chem 272, 1550115509.
  • 84
    Akita K, Toda M, Hosoki Y, Inoue M, Fushiki S, Oohira A, Okayama M, Yamashina I & Nakada H (2004) Heparan sulphate proteoglycans interact with neurocan and promote neurite outgrowth from cerebellar granule cells. Biochem J 383, 129138.
  • 85
    Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan. Curr Opin Cell Biol 14, 617623.
  • 86
    LeBaron RG, Zimmermann DR & Ruoslahti E (1992) Hyaluronate binding properties of versican. J Biol Chem 267, 1000310010.
  • 87
    Zhang Y, Cao L, Kiani CG, Yang BL & Yang BB (1998) The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 273, 3305433063.
  • 88
    Zhang Y, Cao L, Yang BL & Yang BB (1998) The G3 domain of versican enhanced cell proliferation via epidermal growth factor-like motifs. J Biol Chem 273, 2134221351.
  • 89
    Yang BL, Zhang Y, Cao L & Yang BB (1999) Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72, 210220.
  • 90
    Zhang Y, Cao L, Kiani CG, Yang BL, Hu W & Yang BB (1999) Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like repeats. J Cell Biochem 73, 445457.
  • 91
    Zheng PS, Vais D, laPierre D, Liang YY, Lee V, Yang BL & Yang BB (2004) PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 117, 58875895.
  • 92
    McVey GF, Dudhia J & Day AJ (2001) Recombinant expression of link protein, aggrecan and versican. Int J Exp Pathol 82, A1A25.
  • 93
    Zimmermann DR, Dours-Zimmermann MT, Schubert M & Bruckner-Tuderman L (1994) Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 124, 817825.
  • 94
    Milev P, Maurel P, Chiba A, Mievissen M, Popp S, Yamaguchi Y, Margolis RK & Margolis RU (1998) Differential regulation of expression of hyaluronan-binding proteoglycans in developing brain: aggrecan, versican, neurocan and brevican. Biochem Biophys Res Commun 247, 207212.
  • 95
    Ujita M, Shinomura T, Ito K, Kitagawa Y & Kimata K (1994) Expression and binding activity of the carboxyl-terminal portion of the core protein of PG-M, a large chondroitin sulfate proteoglycan. J Biol Chem 269, 2760327609.
  • 96
    Aspberg A, Binkert C & Ruoslahti E (1995) The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Proc Natl Acad Sci USA 92, 1059010594.
  • 97
    Aspberg A, Adam S, Kostka G, Timpl R & Heinegärd D (1999) Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 274, 2044420449.
  • 98
    Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK & Ricciardelli C (2011) Veriscan induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis 28, 113125.
  • 99
    Ang YC, Zhang Y, Cao L, Yang BL, Young B, Kiani CG, Lee V, Allan K & Yang BB (1999) Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58, 597605.
  • 100
    Hudson KA, Abndrews K, Early J, Mjaatvedt CH & Capehart AA (2010) Versican G1 domain and V3 isoform overexpression results in increased chondrogenesis in the developing chick limb in ovo. Anat Rec (Hoboken) 293, 16691678.
  • 101
    Seyfried NT, McVey GF, Almond A, Mahoney DJ, Dudhia J & Day AJ (2005) Expression and purification of functionally active hyaluronan-binding domains from human cartilage link protein, aggrecan and versican: formation of ternary complexes with defined hyaluronan oligosaccharides. J Biol Chem 280, 54355448.
  • 102
    Ney A, Booms P, Epple G, Mörgelin M, Guo G, Kettelgerdes G, Gessner R & Robinson PN (2006) Calcium-dependent self-association of the C-type lectin domain of versican. Int J Biochem Cell Biol 38, 2329.
  • 103
    Olin AI, Mörgelin M, Sasaki T, Timpl R, Heinegård D & Aspberg A (2001) The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem 276, 12531261.
  • 104
    Enghild JJ, Thøgersen IB, Pizzo SV & Salvesen G (1989) Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem 264, 1597515981.
  • 105
    Enghild JJ, Salvesen G, Thogersen IB, Valnickova Z, Pizzo SV & Hefta SA (1993) Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-α-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem 268, 87118716.
  • 106
    Fries E & Blom AM (2000) Bikunin – not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 32, 125137.
  • 107
    Michalski C, Piva F, Balduyck M, Mizon C, Burnouf T, Huart JJ & Mizon J (1994) Preparation and properties of a therapeutic inter-alpha-trypsin inhibitor concentrate from human plasma. Vox Sang 67, 329336.
  • 108
    Bratt T, Olsson H, Sjöberg M, Jergil B & Akerström B (1993) Cleavage of the α1-microglobulin–bikunin precursor in the Golgi apparatus of rat liver cells. Biochim Biophys Acta 1157, 147154.
  • 109
    Chi L, Wolff JJ, Laremore TN, Restaino OF, Xie J, Schiraldi C, Toida T, Amster IJ & Linhardt RJ (2008) Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc 130, 26172625.
  • 110
    Enghild JJ, Salvesen G, Hefta SA, Thøgersen IB, Rutherfurd S & Pizzo SV (1991) Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem 266, 747751.
  • 111
    Martin-Vandelet N, Paris S, Bourguignon J, Sesboüé R, Martin JP & Diarra-Mehrpour M (1999) Assembly and secretion of recombinant chains of human inter-α-trypsin inhibitor in COS-7 cells. Eur J Biochem 259, 476484.
  • 112
    Brinkmann T, Schäfers J, Gürtler L, Kido H, Niwa Y, Katunuma N & Tschesche H (1997) Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV1 replication in H9 cells by recombinant aprotinin and bikunin homologues. J Protein Chem 16, 651660.
  • 113
    Gou XH, Liu YY, Chen QL, Tang JJ, Liu DY, Zou L, Wu XY & Wang W (2012) High level expression of bikunin in Pichia pastoris by fusion of human serum albumin. AMB Express 2, 17.
  • 114
    Wang J, Yan F, Wang D, Ban L, Sun N, Li C, Zhang T & Yan W (2008) Expression and purification of active recombinant human bikunin in Pichia pastoris. Protein Expr Purif 60, 127131.
  • 115
    Bratt T & Akerstrom B (1995) Expression of rat alpha(1)-microglobulin-bikunin in baculovirus-transformed insect cells. Protein Expr Purif 6, 431438.
  • 116
    Blom AM, Thuveson M & Fries E (1997) Intracellular coupling of bikunin and the heavy chain of rat pre-α-inhibitor in COS-1 cells. Biochem J 328, 185191.
  • 117
    Kobayashi H, Shinohara H, Ohi H, Sugimura M, Terao T & Fujie M (1994) Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 12, 117128.
  • 118
    Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D & Terao T (1995) Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 270, 83618366.
  • 119
    Li S, Shimono C, Norioka N, Nakano I, Okubo T, Yagi Y, Hayashi M, Sato Y, Fujisaki H, Hattori S et al. (2010) Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J Biol Chem 285, 3664536655.
  • 120
    Dolan M, Horchar T, Rigatti B & Hassell JR (1997) Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem 272, 43164322.
  • 121
    Kokenyesi R & Silbert JE (1995) Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun 211, 262267.
  • 122
    Groffen AJ, Buskens CA, Tryggvason K, Veerkamp JH, Monnens LA & van den Heuvel LP (1996) Expression and characterization of human perlecan domains I and II synthesized by baculovirus-infected insect cells. Eur J Biochem 241, 827834.
  • 123
    Costell M, Mann K, Yamada Y & Timpl R (1997) Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur J Biochem 243, 115121.
  • 124
    Graham LD, Whitelock JM & Underwood PA (1999) Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 256, 542548.
  • 125
    Yang WD, Gomes RR Jr, Alicknavitch M, Farach-Carson MC & Carson DD (2005) Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng 11, 7689.
  • 126
    Muthusamy A, Cooper CR & Gomes RR Jr (2010) Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells. BMC Biochem 11, 43.
  • 127
    Ellis AL, Pan W, Yang G, Jones K, Chuang C, Whitelock JM & DeCarlo AA (2010) Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1. BMC Biotechnol 10, 66.
  • 128
    Casper CL, Yang W, Farach-Carson MC & Rabolt JF (2007) Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 8, 11161123.
  • 129
    DeCarlo AA, Belousova M, Ellis AL, Petersen D, Grenett H, Hardigan P, O'Grady R, Lord M & Whitelock JM (2012) Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis. BMC Biotechnol 12, 60.
  • 130
    Sasaki T, Costell M, Mann K & Timpl R (1998) Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett 435, 169172.
  • 131
    Costell M, Sasaki T, Mann K, Yamada Y & Timpl R (1996) Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan. FEBS Lett 396, 127131.
  • 132
    Murdoch AD, Liu B, Schwarting R, Tuan RS & Iozzo RV (1994) Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42, 239249.
  • 133
    Schulze B, Mann K, Battistutta R, Wiedemann H & Timpl R (1995) Structural properties of recombinant domain III of perlecan containing a globular domain inserted into an epidermal-growth-factor-like motif. Eur J Biochem 231, 551556.
  • 134
    Gohring W, Sasaki T, Heldin CH & Timpl R (1998) Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur J Biochem 255, 6066.
  • 135
    Chakravarti S, Horchar T, Jefferson B, Laurie GW & Hassell JR (1995) Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J Biol Chem 270, 404409.
  • 136
    Allen JM, Bateman JF, Hansen U, Wilson R, Bruckner P, Owens RT, Sasaki T, Timpl R & Fitzgerald J (2006) WARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecan. J Biol Chem 281, 73417349.
  • 137
    Hopf M, Gohring W, Mann K & Timpl R (2001) Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J Mol Biol 311, 529541.
  • 138
    Hopf M, Gohring W, Kohfeldt E, Yamada Y & Timpl R (1999) Recombinant domain IV of perlecan binds to nidogens, laminin–nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem 259, 917925.
  • 139
    Kohfeldt E, Sasaki T, Gohring W & Timpl R (1998) Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282, 99109.
  • 140
    Brown JC, Sasaki T, Gohring W, Yamada Y & Timpl R (1997) The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 250, 3946.
  • 141
    Friedrich MV, Gohring W, Morgelin M, Brancaccio A, David G & Timpl R (1999) Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 294, 259270.
  • 142
    Tapanadechopone P, Hassell JR, Rigatti B & Couchman JR (1999) Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun 265, 680690.
  • 143
    Jung M, Lord MS, Cheng B, Lyons JG, Alkhouri H, Hughes M, McCarthy S, Iozzo RV & Whitelock JM (2013) Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing. J Biol Chem 288, 32893304.
  • 144
    Mongiat M, Sweeney SM, San Antonio JD, Fu J & Iozzo RV (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C-terminus of perlecan. J Biol Chem 278, 42384249.
  • 145
    Friedrich MV, Schneider M, Timpl R & Baumgartner S (2000) Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression. Eur J Biochem 267, 31493159.
  • 146
    Ettner N, Gohring W, Sasaki T, Mann K & Timpl R (1998) The N-terminal globular domain of the laminin alpha1 chain binds to alpha1beta1 and alpha2beta1 integrins and to the heparan sulfate-containing domains of perlecan. FEBS Lett 430, 217221.
  • 147
    Bengtsson E, Morgelin M, Sasaki T, Timpl R, Heinegard D & Aspberg A (2002) The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J Biol Chem 277, 1506115068.
  • 148
    Talts JF, Andac Z, Gohring W, Brancaccio A & Timpl R (1999) Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 18, 863870.
  • 149
    Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Hook M et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166, 97109.
  • 150
    Adam E, Sarrazin S, Landolfi C, Motte V, Lortat-Jacob H, Lassalle P & Delehedde M (2008) Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor. Biochem Biophys Res Commun 369, 297302.
  • 151
    Chang Z, Choon A & Friedl A (1999) Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 155, 7176.
  • 152
    Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E & Timpl R (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 18, 62406248.
  • 153
    O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR & Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277285.
  • 154
    Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkila P, Rehn M, Sorsa T, Salo T & Pihlajaniemi T (2005) Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 307, 292304.
  • 155
    Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E & Timpl R (2000) Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 301, 11791190.
  • 156
    Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B & Sukhatme VP (1999) Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255, 735739.
  • 157
    Li D, Clark CC & Myers JC (2000) Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells. J Biol Chem 275, 2233922347.
  • 158
    Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D & Myers JC (2005) Proteoglycan-collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. J Histochem Cytochem 53, 165176.
  • 159
    Hagg PM, Hagg PO, Peltonen S, Autio-Harmainen H & Pihlajaniemi T (1997) Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol 150, 20752086.
  • 160
    Hurskainen M, Ruggiero F, Hagg P, Pihlajaniemi T & Huhtala P (2010) Recombinant human collagen XV regulates cell adhesion and migration. J Biol Chem 285, 52585265.
  • 161
    Romaris M, Coomans C, Ceulemans H, Bruystens AM, Vekemans S & David G (1999) Molecular polymorphism of the syndecans. Identification of a hypo-glycanated murine syndecan-1 splice variant. J Biol Chem 274, 1866718674.
  • 162
    Carulli S, Beck K, Dayan G, Boulesteix S, Lortat-Jacob H & Rousselle P (2012) Cell surface proteoglycans syndecan-1 and -4 bind overlapping but distinct sites in laminin alpha3 LG45 protein domain. J Biol Chem 287, 1220412216.
  • 163
    McQuade KJ, Beauvais DM, Burbach BJ & Rapraeger AC (2006) Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J Cell Sci 119, 24452456.
  • 164
    Fitzgerald ML, Wang Z, Park PW, Murphy G & Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811824.
  • 165
    Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M & Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278, 4076440770.
  • 166
    Zong F, Fthenou E, Mundt F, Szatmari T, Kovalszky I, Szilak L, Brodin D, Tzanakakis G, Hjerpe A & Dobra K (2011) Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS ONE 6, e14816.
  • 167
    Whiteford JR & Couchman JR (2006) A conserved NXIP motif is required for cell adhesion properties of the syndecan-4 ectodomain. J Biol Chem 281, 3215632163.
  • 168
    Viklund L, Loo BM, Hermonen J, El-Darwish K, Jalkanen M & Salmivirta M (2002) Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein. Biochem Biophys Res Commun 290, 146152.
  • 169
    Yoneda A, Asada M, Oda Y, Suzuki M & Imamura T (2000) Engineering of an FGF–proteoglycan fusion protein with heparin-independent, mitogenic activity. Nat Biotechnol 18, 641644.
  • 170
    Steinfeld R, Van Den Berghe H & David G (1996) Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133, 405416.
  • 171
    Hagihara K, Watanabe K, Chun J & Yamaguchi Y (2000) Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 219, 353367.
  • 172
    Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD & Sanderson RD (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 273, 2282522832.
  • 173
    Gengrinovitch S, Berman B, David G, Witte L, Neufeld G & Ron D (1999) Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274, 1081610822.
  • 174
    Zhang F, Ronca F, Linhardt RJ & Margolis RU (2004) Structural determinants of heparan sulfate interactions with Slit proteins. Biochem Biophys Res Commun 317, 352357.
  • 175
    Zittermann SI, Capurro MI, Shi W & Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126, 12911301.
  • 176
    Svensson G & Mani K (2009) S-Nitrosylation of secreted recombinant human glypican-1. Glycoconj J 26, 12471257.
  • 177
    Chen RL & Lander AD (2001) Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 276, 75077517.
  • 178
    Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G & Aruffo A (1995) CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128, 687698.
  • 179
    Piepkorn M, Hovingh P, Bennett KL & Linker A (1999) Heparan sulfate composition of alternatively spliced CD44 fusion proteins. Biochem Biophys Res Commun 257, 839842.
  • 180
    Nishiyama A & Stallcup WB (1993) Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol Biol Cell 4, 10971108.
  • 181
    Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ & Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93, 97109715.
  • 182
    Schrappe M, Klier FG, Spiro RC, Waltx TAR, Reisfeld RA & Gladson CL (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51, 49864993.
  • 183
    Leger O, Johnson-Leger C, Jackson E, Coles B & Dean C (1994) The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer 58, 700705.
  • 184
    Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favino E, Koya Y, Campoli MR et al. (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10, 419429.
  • 185
    Tillet E, Ruggiero F, Nishiyama A & Stallcup WB (1997) The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J Biol Chem 272, 1076910776.
  • 186
    Ughrin YM, Chen ZJ & Levine JM (2003) Multiple regions of the NG2 proteoglycan inhibit neurite growth and induce growth cone collapse. J Neurosci 23, 175186.
  • 187
    Burg MA, Nishiyama A & Stallcup WB (1997) A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp Cell Res 235, 254264.
  • 188
    Tillet E, Gential B, Garrone R & Stallcup WB (2002) NG2 proteoglycan mediates β1 integrin-independent cell adhesion and spreading on collagen VI. J Cell Biochem 86, 726736.
  • 189
    Burg MA, Tillet E, Timpl R & Stallcup WB (1996) Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J Biol Chem 271, 2611026116.
  • 190
    Goretzki L, Burg MA, Grako KA & Stallcup WB (1999) High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 274, 1683116837.
  • 191
    Schick BP, Gradowski JF & San Antonio JD (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97, 449458.
  • 192
    Braga T, Grujic M, Lukinius A, Hellman L, Abrink M & Pejler G (2007) Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. Biochem J 403, 4957.
  • 193
    Biederbick A, Licht A & Kleene R (2003) Serglycin proteoglycan is sorted into zymogen granules of rat pancreatic acinar cells. Eur J Cell Biol 82, 1929.
  • 194
    Hafte TT, Fagereng GL, Prydz K, Grondahl F & Tveit H (2011) Protein core-dependent glycosaminoglycan modification and glycosaminoglycan-dependent polarized sorting in epithelial Madin–Darby canine kidney cells. Glycobiology 21, 457466.
  • 195
    Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D et al. (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71, 31623172.
  • 196
    Hasegawa K, Yoneda M, Kuwabara H, Miyaishi O, Itano N, Ohno A, Zako M & Isogai Z (2007) Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding ability in solar elastosis. J Invest Dermatol 127, 16571663.
  • 197
    Naso MF, Zinmmermann DR & Iozzo RV (1994) Characterisation of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 269, 3299933008.